HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Medical Aspects

2006 ◽  
pp. 168-172
Author(s):  
H. Krebs ◽  
M. M. Schneider ◽  
W. Schramm
Keyword(s):  
Retrospective Study ◽  
Hemophilia A ◽  
Hcv Infection ◽  
Infected People

scholarly journals HCV Detection, Discrimination, and Genotyping Technologies

Sensors ◽  
2018 ◽  
Vol 18 (10) ◽  
pp. 3423 ◽  
Author(s):  
Shrikant Warkad ◽  
Satish Nimse ◽  
Keum-Soo Song ◽  
Taisun Kim
Keyword(s):  
Hepatitis C ◽  
Hcv Infection ◽  
World Health ◽  
Clinical Samples ◽  
Infected People ◽  
Advantages And Disadvantages ◽  
Highly Sensitive ◽  
The World ◽  
Health Organization

According to the World Health Organization (WHO), 71 million people were living with Hepatitis C virus (HCV) infection worldwide in 2015. Each year, about 399,000 HCV-infected people succumb to cirrhosis, hepatocellular carcinoma, and liver failure. Therefore, screening of HCV infection with simple, rapid, but highly sensitive and specific methods can help to curb the global burden on HCV healthcare. Apart from the determination of viral load/viral clearance, the identification of specific HCV genotype is also critical for successful treatment of hepatitis C. This critical review focuses on the technologies used for the detection, discrimination, and genotyping of HCV in clinical samples. This article also focuses on advantages and disadvantages of the reported methods used for HCV detection, quantification, and genotyping.

Sa1072 Single Centre Retrospective Study of Hepatitis C (HCV) Infection and Outcome in Patients With Bleeding Disorders Having Received Blood Products in the UK Prior to 1991

2013 ◽  
Vol 144 (5) ◽  
pp. S-989-S-990
Author(s):  
Thendral K. Mangala Murugesan ◽  
Qurat Tak ◽  
Samuel Ackroyd ◽  
Sulleman Moreea
Keyword(s):  
Retrospective Study ◽  
Hepatitis C ◽  
Hcv Infection ◽  
Bleeding Disorders ◽  
Blood Products ◽  
Single Centre ◽  
The Uk

scholarly journals Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies

Sensors ◽  
2019 ◽  
Vol 19 (19) ◽  
pp. 4257 ◽  
Author(s):  
Warkad ◽  
Song ◽  
Pal ◽  
Nimse
Keyword(s):  
Acute Infection ◽  
Health Sector ◽  
High Sensitivity ◽  
Global Scale ◽  
Hcv Infection ◽  
Infected People ◽  
Chronic Hcv Infection ◽  
Hcv Screening ◽  
Chronic Hcv ◽  
Sensitivity Specificity

Hepatitis C virus (HCV) accounts for 15%–20% of cases of acute infection, and chronic HCV infection is developed in about 50%–80% of HCV patients. Unfortunately, due to the lack of proper medical care, difficulty in screening for HCV infection, and lack of awareness resulted in chronic HCV infection in 71 million people on a global scale, and about 399,000 deaths in 2016. It is crucial to recognize that the effective use of antiviral medicines can cure more than 95% of HCV infected people. The Global Health Sector Strategy (GHSS) aim is to reduce the new HCV infections and the HCV associated mortality by 90% and 65%, respectively. Therefore, the methods that are simple, yet powerful enough to detect HCV infections with high sensitivity, specificity, and a shorter window period are crucial to restrain the global burden of HCV healthcare. This article focuses on the technologies used for the detection of HCV in clinical specimens.

scholarly journals Rising trends of HCV infection over a period of 4 years among blood donors in central India: A retrospective study

2013 ◽  
Vol 3 (4) ◽  
pp. 240 ◽  
Author(s):  
Alok Kumar ◽  
Satish Sharma ◽  
Narayan Ingole ◽  
Nitin Gangane
Keyword(s):  
Retrospective Study ◽  
Blood Donors ◽  
Central India ◽  
Hcv Infection

scholarly journals THE PREVALENCE OF HEPATITIS C VIRUS INFECTION AND POTENTIAL RISK FACTORS AMONG MULTIPLY TRANSFUSED PATIENTS

2019 ◽  
Vol 12 (1) ◽  
pp. 473
Author(s):  
Manal Khudder Abdul Razak
Keyword(s):  
Risk Factors ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Potential Risk ◽  
Hemophilia A ◽  
Von Willebrand Disease ◽  
Hcv Infection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cross Sectional ◽  
Potential Risk Factors

Objective: Patients who frequently receive blood have high risk of hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of HCV infection and potential risk factors among multiply transfused patients.Methods: A cross-sectional retrospective study was conducted in the hemophilia unit in Medical City in Baghdad, between June 1, 2016, and January 1, 2017. After taking consents and approval of ethical comity, the medical records of 1158 patients with hemophilia A and B, von Willebrand disease (vWD), thrombasthenia, Factors VII, X, and XIII deficiencies, and hypofibrinogenemia were analyzed for the presence of HCV antibody using (enzyme-linked immunosorbent assay). Cases of hemophilia were classified into mild, moderate, and severe.Results: The prevalence of HCV infection was 13.2%. Of total, 595 (51.4%) patients had hemophilia A and 99 (16.6%) were anti-HCV positive, while 225 (19.4%) had hemophilia B and 28 (12.4%) were antibody positive compared to 9 (7%) in vWD. Of those with hemophilia A, 515 (86.6%) had severe hemophilia, and 32 (32.32%) cases had acquired HCV infection after 1996 (after introduction of HCV screening in blood banks in Iraq). There was a statistically significant association with treatment by Factor VIII only.Conclusion: The prevalence of HCV in patients with inherited bleeding disorder is 13.2%. In this study, it was found that multitransfusion is the only predictor for HCV infection in this group of patients. 

Retrospective study to assess the impact of hepatitis C virus infection on the prognosis and management of multiple myeloma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20001-e20001
Author(s):  
David Kaldas ◽  
Andrew Wahba ◽  
Radwa Hamdy Azab ◽  
Ehab Mostafa Elnakoury ◽  
Nagla Fawzy Abdel Karim ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Hepatitis C Virus ◽  
Retrospective Study ◽  
Hepatitis C ◽  
Progression Free Survival ◽  
Hcv Infection ◽  
Cytotoxic Agents ◽  
Free Survival ◽  
The Impact

e20001 Background: Multiple Myeloma (MM) is a neoplasm of the post-germinal center, terminally differentiated B-cells. MM accounts for 1% of all types of cancer and 10% for all hematologic malignancies. Chronic hepatitis C virus (HCV) is an infection that affects over 71 million patients worldwide. Cytotoxic agents and immunosuppressive therapy as steroids are the main line of therapy in lymphoid malignancies, but these drugs may exacerbate chronic viral hepatitis and cause uncontrolled replication of hepatitis viruses. The impact of HCV infection on MM patients remains unclear. Objective: To assess the impact of HCV infection on the prognosis and management of MM patients. Methods: A 10-year retrospective study of MM patients was conducted at Cairo University Clinical Oncology Department from January 2009 to April 2019. Results: During this time, 150 patients were diagnosed with MM, 109 (72.7%) were HCV negative, 24 (16%) were HCV positive, and 17 (11.3%) with unknown HCV status. The median age was 51 and 54 years for HCV negative and positive groups respectively, with a statistically insignificant difference (p-value > 0.2). In the multivariate analysis, HCV infection was not an independent factor related to overall survival (OS), however age, creatinine and hemoglobin levels correlated significantly with OS (p < 0.009, 0.008, 0.031 respectively). The median OS for the HCV negative group was 31.11 months (95% CI: 22.62 - 39.61) compared to 37.66 months (95% CI: 7.19 - 68.13) for the HCV positive group. The median progression-free survival (PFS) for all patients was 18.9 months, for HCV positive patients was 15.36 months (95% CI: 13.18 – 17.54), and for HCV negative patients was 20.49 months (95% CI: 14.13 – 26.85). Age below 60 years and creatinine level less than 2 mg/dL were statistically significant for favorable disease-free survival (DFS) (p < 0.030, 0.034 respectively). Conclusions: Age, creatinine and hemoglobin levels are significant prognostic factors in MM but HCV status doesn’t affect the overall survival or progression-free survival. HCV infection should not contraindicate MM therapy.

scholarly journals Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study

2016 ◽  
Vol 33 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Yunus Gurbuz ◽  
Necla Eren Tulek ◽  
Emin Ediz Tutuncu ◽  
Suda Tekin Koruk ◽  
Bilgehan Aygen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Real Life ◽  
Dual Therapy ◽  
Hcv Infection ◽  
Real Life Setting ◽  
Treatment Naïve ◽  
Turkish Patients

scholarly journals Hepatitis B and C Virus Infections among Blood Donors in Blood Transfusion Center, Pokhara, Nepal: Seroprevalence and its Associated Risk Factors

2019 ◽  
Vol 6 (1) ◽  
pp. 33-38
Author(s):  
Gyanendra Bikram Shah ◽  
Krishna Gurung ◽  
Bharat Prasad Baral ◽  
Ram Raja Gurung ◽  
Balkrishna Bhattachan
Keyword(s):  
Risk Factors ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Infection Rate ◽  
Blood Donors ◽  
Cross Sectional Study ◽  
Hcv Infection ◽  
Volunteer Blood Donor ◽  
Cross Sectional ◽  
Infected People

Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections lead to chronic diseases and are the most common causes of liver cirrhosis and cancer in developing countries like Nepal. The study is carried out to determine the seroprevalence of HBV and HCV by using a Rapid kit method and Elisa Method to find out its risk factors. The cross-sectional study was done among blood donating people from 16th August 2016 to 19th November 2016. Blood donors in Pokhara Valley were screened for anti-HCV antibodies, anti-HBV antibodies using third generation ELISA kits and automated ELISA Processor in serology laboratory at Central Blood Transfusion Service (CBTS) of Nepal Red Cross Society (NRCS) in Pokhara, Nepal. 1777 (87.2%) units were male blood donors and 260 (12.6%) units were female donors out of 2037 participants. Gender wise, the ratio between male and female was 1:0.1. HBV and HCV infection rate in blood donors were detected at 0.7% (15/2037) and 0.5% (8/2037) respectively. HBV infection rate in volunteer blood donor people was 0.7% (14/1881) which was higher than the replacement donors i.e. 0.6% (1/156). Similarly, in HCV infection rate in volunteer donor were 0.4% (8/1881). HBV infected people are detected higher than the HCV infected people among the blood donors. In addition, there was no significant relationship between positive results of HBV and HCV tests with the gender, age, tattoo, donor type.

Sign in / Sign up

Export Citation Format

Share Document